XTX Topco Ltd Buys 94,943 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

XTX Topco Ltd increased its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 720.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 108,120 shares of the biotechnology company's stock after purchasing an additional 94,943 shares during the period. XTX Topco Ltd owned approximately 0.22% of REGENXBIO worth $836,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also modified their holdings of the company. JPMorgan Chase & Co. increased its position in shares of REGENXBIO by 67.0% during the 4th quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock worth $31,975,000 after purchasing an additional 1,659,206 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of REGENXBIO by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,094,225 shares of the biotechnology company's stock valued at $8,460,000 after purchasing an additional 5,574 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in REGENXBIO by 53.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock worth $6,621,000 after purchasing an additional 296,700 shares during the period. Norges Bank acquired a new position in shares of REGENXBIO in the fourth quarter valued at approximately $3,474,000. Finally, Renaissance Technologies LLC acquired a new stake in REGENXBIO in the fourth quarter valued at about $2,097,000. Institutional investors and hedge funds own 88.08% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on RGNX shares. Chardan Capital restated a "buy" rating and issued a $52.00 price objective on shares of REGENXBIO in a research report on Thursday, March 20th. Raymond James assumed coverage on shares of REGENXBIO in a report on Friday, February 7th. They issued an "outperform" rating and a $27.00 price target for the company. HC Wainwright decreased their target price on REGENXBIO from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday, March 17th. Morgan Stanley increased their price objective on REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, March 14th. Finally, StockNews.com upgraded REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, March 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $31.63.

REGENXBIO Price Performance

Shares of RGNX stock traded down $0.22 on Friday, hitting $5.94. The stock had a trading volume of 649,002 shares, compared to its average volume of 802,506. The stock has a market cap of $297.69 million, a price-to-earnings ratio of -1.18 and a beta of 1.26. The business has a 50 day moving average of $6.81 and a 200 day moving average of $8.14. REGENXBIO Inc. has a 12-month low of $5.04 and a 12-month high of $17.52.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, beating analysts' consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The business had revenue of $21.21 million for the quarter, compared to analysts' expectations of $23.70 million. As a group, research analysts expect that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.